menu

CME: Severe Asthma and Related Eosinophilic Diseases: The Role of IL-5 in Diagnosis and Treatment

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Severe Asthma and Related Eosinophilic Diseases: The Role of IL-5 in Diagnosis and Treatment

close
3 chapters
Play All
0.75 credits
Chapter 1
Severe Asthma and Related Eosinophilic Diseases: The Role of IL-5 in Diagnosis and Treatment
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Chapter 2
video Differential Diagnosis of Severe Asthma and Associated Eosinophilic Diseases for Segment 11302
Differential Diagnosis of Severe Asthma and Associated Eosinophilic Diseases
Chapter 3
video Treatment Selection for the Spectrum of Eosinophilic Diseases for Segment 11302
Treatment Selection for the Spectrum of Eosinophilic Diseases
Details
Presenters
Related
Comments
  • Overview

    This 45-minute enduring activity (three 15 minute chapters) covers the role of eosinophils and type 2 inflammation in severe asthma and eosinophil-related diseases. Understanding how to identify the mechanisms of action for biologic therapies can aid providers in selecting appropriate treatments for patients with these diseases. Using the clinical presentation and diagnostic test results, providers will learn about current and emerging treatments and recent clinical studies on approved agents that can help with treatment selection and indications of when it is appropriate to refer to a specialist. 

  • Disclosure of Conflicts of Interest

    Faculty Disclosures

    Eileen Wang, MD, MPH
    Dr. Wang discloses that she is on an advisory board for AstraZeneca and an investigator for Optimum Patient Care Limited, GlaxoSmithKline, Self Care Catalysts and Genentech.

    Ron Balkissoon, MD
    Dr. Balkissoon discloses that he is on an advisory board a consultant and a speaker for AstraZeneca, GlaxoSmithKline, Sanofi/Regeneron and Genentech/Novartis.

    Planner and Reviewer Disclosures

    Laurie Manka, MD
    Dr. Manka discloses that she is an investigator for AstraZeneca, Teva and Health Care Catalysts.

    None of the following individuals who served as planners or reviewers have any relevant financial relationships to disclose:
    Stephanie Corder, ND, RN, CHCP
    Andrea Harshman, MHA, CHCP, CMP-HC
    Aubrey Shoe, MA

    Disclosure of Unlabeled Use

    The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

    No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

    Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

  • Target Audience

    This activity has been designed to meet the educational needs of Allergists, Pulmonologists, Otolaryngologists (ENTs), Rhinologists, Rheumatologists as well as Primary Care/Family Medicine/Internal Medicine Physicians and Advance Practice Providers (APPs) who diagnose and treat allergic and pulmonary diseases.

  • Learning Objectives

    Chapter 1: Pathophysiology, Identification, Diagnosis, Biomarkers and Subtypes (15 min)
    Learning Objectives:
    Describe the role of eosinophils and type 2 inflammation in severe asthma and eosinophil-associated diseases.

    Identify the mechanisms of action of biologic therapies for severe asthma and eosinophil-associated diseases

    Chapter 2: Differential Diagnosis of Severe Asthma and Associated Eosinophilic Diseases (15 min)
    Learning Objective:
    Distinguish severe asthma and related eosinophilic diseases from one another using clinical presentation and diagnostic test results.

    Chapter 3: Treatment Selection for the Spectrum of Eosinophilic Diseases (15 min)
    Learning Objective:
    Apply the results of clinical studies that examine the tolerability, efficacy, and safety of approved agents when selecting and monitoring therapy for severe asthma and associated eosinophilic diseases.

  • Accreditation and Credit Designation Statements

    Accreditation Statement
    National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Designation Statement
    Physicians: National Jewish Health designates this online enduring educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Disclaimer
    National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.


    By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

    Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This educational activity is supported by an educational grant from GlaxoSmithKline.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    This 45-minute enduring activity (three 15 minute chapters) covers the role of eosinophils and type 2 inflammation in severe asthma and eosinophil-related diseases. Understanding how to identify the mechanisms of action for biologic therapies can aid providers in selecting appropriate treatments for patients with these diseases. Using the clinical presentation and diagnostic test results, providers will learn about current and emerging treatments and recent clinical studies on approved agents that can help with treatment selection and indications of when it is appropriate to refer to a specialist. 

  • Disclosure of Conflicts of Interest

    Faculty Disclosures

    Eileen Wang, MD, MPH
    Dr. Wang discloses that she is on an advisory board for AstraZeneca and an investigator for Optimum Patient Care Limited, GlaxoSmithKline, Self Care Catalysts and Genentech.

    Ron Balkissoon, MD
    Dr. Balkissoon discloses that he is on an advisory board a consultant and a speaker for AstraZeneca, GlaxoSmithKline, Sanofi/Regeneron and Genentech/Novartis.

    Planner and Reviewer Disclosures

    Laurie Manka, MD
    Dr. Manka discloses that she is an investigator for AstraZeneca, Teva and Health Care Catalysts.

    None of the following individuals who served as planners or reviewers have any relevant financial relationships to disclose:
    Stephanie Corder, ND, RN, CHCP
    Andrea Harshman, MHA, CHCP, CMP-HC
    Aubrey Shoe, MA

    Disclosure of Unlabeled Use

    The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

    No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

    Please refer to the official prescribing information for each product for discussion of approved indicators, contraindications and warnings.

  • Target Audience

    This activity has been designed to meet the educational needs of Allergists, Pulmonologists, Otolaryngologists (ENTs), Rhinologists, Rheumatologists as well as Primary Care/Family Medicine/Internal Medicine Physicians and Advance Practice Providers (APPs) who diagnose and treat allergic and pulmonary diseases.

  • Learning Objectives

    Chapter 1: Pathophysiology, Identification, Diagnosis, Biomarkers and Subtypes (15 min)
    Learning Objectives:
    Describe the role of eosinophils and type 2 inflammation in severe asthma and eosinophil-associated diseases.

    Identify the mechanisms of action of biologic therapies for severe asthma and eosinophil-associated diseases

    Chapter 2: Differential Diagnosis of Severe Asthma and Associated Eosinophilic Diseases (15 min)
    Learning Objective:
    Distinguish severe asthma and related eosinophilic diseases from one another using clinical presentation and diagnostic test results.

    Chapter 3: Treatment Selection for the Spectrum of Eosinophilic Diseases (15 min)
    Learning Objective:
    Apply the results of clinical studies that examine the tolerability, efficacy, and safety of approved agents when selecting and monitoring therapy for severe asthma and associated eosinophilic diseases.

  • Accreditation and Credit Designation Statements

    Accreditation Statement
    National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Designation Statement
    Physicians: National Jewish Health designates this online enduring educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Disclaimer
    National Jewish Health ("NJH") and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, "NJH Parties") shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be.


    By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product.

    Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This educational activity is supported by an educational grant from GlaxoSmithKline.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/27/20